TransForm Earns Performance Milestone In Lilly Collaboration

TransForm Pharmaceuticals, Inc. has received a $1 million performance milestone payment from its partner, Eli Lilly and Company, under their collaboration. The performance payment was contingent on TransForm attaining several critical success factors by the end of 2002 as outlined in the agreement. TransForm and Lilly entered into their multi-year collaboration earlier in 2002 to Read more about TransForm Earns Performance Milestone In Lilly Collaboration[…]

Geron And University Of California, Irvine Awarded BioSTAR Grant

Geron Corporation has announced the renewal of a matching grant from the University of California BioSTAR Project to support continued research on the use of human embryonic stem cells (hESCs) to derive oligodendrocytes for the treatment of spinal cord and related central nervous system (CNS) injuries. The work, originally initiated in August 2001 with Geron Read more about Geron And University Of California, Irvine Awarded BioSTAR Grant[…]

Luminex Announces Letter Of Intent To Sell RBM

Luminex Corporation has announced it has entered into a nonbinding letter of intent to divest its Rules-Based Medicine research and development project (“RBM”) to a newly formed company to be headed by Dr. Mark B. Chandler, Luminex’s current Chairman, President and Chief Executive Officer. RBM uses the Luminex xMAP(TM) technology to analyze a large number Read more about Luminex Announces Letter Of Intent To Sell RBM[…]

Ribotargets Receives Exclusive Ribosome License

RiboTargets has received an exclusive worldwide license to patents filed by the Medical Research Council (MRC) relating to the 30S subunit of the bacterial ribosome (30S). Pioneering research led by the MRC’s Dr Venki Ramakrishnan has elucidated the molecular structure of the 30S bacterial ribosome and the molecular interactions that enable ribosomes to assemble proteins Read more about Ribotargets Receives Exclusive Ribosome License[…]

PPD Discovery Licenses Its Pharmazyme Technology

PPD Discovery, a wholly-owned subsidiary of PPD, Inc. has established a relationship with New England Biolabs, Inc. (NEB) to produce and sell recombinant human cytochrome P450 (CYP450) enzymes expressed in bacteria using PPD Discovery’s proprietary Pharmazyme technology. Under the terms of the agreement, NEB receives a non-exclusive license to make and sell human CYP450 enzymes Read more about PPD Discovery Licenses Its Pharmazyme Technology[…]

RiboTargets And Sun Microsystems Collaborate

RiboTargets and Sun Microsystems Inc. have entered into a collaboration using high-powered computing methods to discover a novel class of antibiotic. In the collaboration, Sun committed a 200 processor SUN TCF (Technical Compute Farm) on which RiboTargets has been running its unique virtual screening software RiboDock. The software is designed to screen huge numbers of Read more about RiboTargets And Sun Microsystems Collaborate[…]

Applied Molecular Evolution, Lilly Agree Second Collaboration

Applied Molecular Evolution Inc. (AME) has agreed to optimize an additional therapeutic antibody candidate for Eli Lilly and Co. In December 2001 AME announced its initial collaboration to optimize an antibody and a non-antibody protein therapeutic for Lilly. The goal of the current collaboration is to apply AME‘s proprietary AMEsystem directed molecular evolution technology to Read more about Applied Molecular Evolution, Lilly Agree Second Collaboration[…]

Pharmacopeia And Organon To Collaborate

Pharmacopeia, Inc. and Organon, the pharmaceutical business unit of Akzo Nobel have announced the formation of a new 5-year drug discovery collaboration. Under the terms of this agreement, Organon will provide Pharmacopeia with numerous biological test systems, or assays. Utilizing these assays, its broad collection of unique and powerful drug discovery technologies, and medicinal chemistry Read more about Pharmacopeia And Organon To Collaborate[…]

Genaissance Signs Agreement With Intec

Genaissance Pharmaceuticals, Inc. has entered into an agreement with INTEC Web & Genome Informatics Corporation to market all of Genaissance’s proprietary pharmacogenomics applications and products to pharmaceutical, diagnostic and biotechnology companies located in Japan. “With INTEC W&G as our Japanese sales representative, Genaissance is expanding its potential market reach to a country that is second Read more about Genaissance Signs Agreement With Intec[…]

Neoprobe Completes License For Lymphatic Agent

Neoprobe Corporation has announced that it has completed an exclusive license agreement with the University of California, San Diego (UCSD). The license affords Neoprobe the rights to a proprietary compound developed by researchers at UCSD. The compound, which Neoprobe has designated Lymphoseek (TM), is being evaluated in clinical studies to determine its effectiveness in identifying Read more about Neoprobe Completes License For Lymphatic Agent[…]